Hørsholm – November 28, 2007 -- 7TM Pharma today announced results from a clinical Phase I/II study with Obinepitide developed for the treatment of obesity and related diseases. The drug candidate Obinepitide has a novel mechanism of action compared to existing drugs for the treatment of obesity and it has the potential to become the first drug on the market with this mechanism. Obinepitide is a close analogue of two natural hormones that are normally released in connection with food intake. Both of these hormones are known to play a role as satiety signals from the gastrointestinal system in connection with food intake and appetite regulation. Obinepitide is unique having incorporated these satiety signals into one compound.
